Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Sequential Cohorts, Flexible Dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Iloperidone in Elderly Patients With Parkinson's Disease Psychosis (PDP)

Next Previous
Trial Profile

An Open-label, Sequential Cohorts, Flexible Dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Iloperidone in Elderly Patients With Parkinson's Disease Psychosis (PDP)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iloperidone (Primary)
  • Indications Parkinson's disease; Psychotic disorders
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Vanda Pharmaceuticals

Most Recent Events

  • 19 Mar 2024 Status changed from recruiting to withdrawn prior to enrolment. (Study was terminated for business reasons; not due to safety or efficacy concerns.)
  • 04 May 2023 According to a Vanda Pharmaceuticals media release, pooled efficacy analysis data from VP-VLY-686-3301 AND VP-VLY-686-2301 will be presented at Digestive Disease Week (DDW) 2023.
  • 01 Jun 2022 Planned initiation date changed from 1 Apr 2022 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top